Evaluation of the correlation between Ki-67 proliferative index and the histopathological grade of invasive neoplasms in early breast cancer aged < 70 years of age: a review of 300 cases
, 3, 1, 1, 1, 4
Abstract
Background and objectives: according to the WHO 2018 reports, breast cancer is the fourth most common cause of cancer deaths worldwide. The breast cancer is recognized as the most common malignancy in the UK, it accounts for about 15% of all newly diagnosed malignancies, followed by prostate (13%), lung (13%), and bowel (11%). Ki-67 proliferative index became a key element in the diagnostic process of breast cancer, in addition to its role as a predictive tool and prognostic marker during the planning of adjuvant therapy as hormonal manipulation of systemic chemotherapy. The study aims to present the correlation analysis between Ki-67 and the different histological grade in breast cancer tumours.
Material and methods: a cohort of 300 patients treated for early breast cancer was included in the study. The demographic data, histopathological subtype, hormonal and HER2 (Human epidermal growth factor receptor-2) receptor status and Ki-67 were analysed. The cut-off point was set at 20% to distinguish “high Ki-67” from “low Ki-67”.
Results: about 35% (n = 106) of the cases were grade II with low Ki-67 , 26% (n = 79) grade III with high Ki-67, 19% (n = 56) grade II with high Ki-67, 11% (n = 34) grade I with low Ki-67. The high Ki-67 seen in 135 patients who belong to grade II and III groups (45%), where low Ki-67 in 42% of those cases, however, grade III alone contained more cases of high Ki-67 than any other histological grade group.
Conclusions: a higher tumour histopathologic grade was correlated with higher Ki-67 values (OR = 7.12, 95% CI 16.75–3.03; p < 0.0001).
Keywords: Ki-67breast cancermammographychemotherapycell cycle
References
- Saad Abdalla Al-Zawi A, Syed A. Ki67 Proliferation index as a prognostic and predictive tool for pathological response after upfront chemotherapy in breast cancer. Paripex Indian Journal of Research. 2020; 9. ; 11.
- Liang Q, Ma D, Gao RF, et al. Effect of Ki-67 Expression Levels and Histological Grade on Breast Cancer Early Relapse in Patients with Different Immunohistochemical-based Subtypes. Sci Rep. 2020; 10(1): 7648.
- Miller I, Min M, Yang C, et al. Ki67 is a Graded Rather than a Binary Marker of Proliferation versus Quiescence. Cell Rep. 2018; 24(5): 1105–1112.e5.
- Maranta AF, Broder S, Fritzsche C, et al. Do you know the Ki-67 index of your breast cancer patients? Knowledge of your institution's Ki-67 index distribution and its robustness is essential for decision-making in early breast cancer. Breast. 2020; 51: 120–126.
- Soliman NA, Yussif SM. Ki-67 as a prognostic marker according to breast cancer molecular subtype. Cancer Biol Med. 2016; 13(4): 496–504.
- Bustreo S, Osella-Abate S, Cassoni P, et al. Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up. Breast Cancer Res Treat. 2016; 157(2): 363–371.
- Inic Z, Zegarac M, Inic M, et al. Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information. Clin Med Insights Oncol. 2014; 8: 107–111.
- Prat A, Pascual T, Adamo B. Intrinsic molecular subtypes of HER2+ breast cancer. Oncotarget. 2017; 8(43): 73362–73363.
- Hashmi AA, Hashmi KA, Irfan M, et al. Ki67 index in intrinsic breast cancer subtypes and its association with prognostic parameters. BMC Res Notes. 2019; 12(1): 605.
- Kanyılmaz G, Yavuz BB, Aktan M, et al. Prognostic Importance of Ki-67 in Breast Cancer and Its Relationship with Other Prognostic Factors. Eur J Breast Health. 2019; 15(4): 256–261.
- Petric M, Martinez S, Acevedo F, et al. Correlation between Ki67 and histological grade in breast cancer patients treated with preoperative chemotherapy. Asian Pac J Cancer Prev. 2014; 15(23): 10277–10280.
- Al-Zawi A. Ki -67 proliferative index as a predictive tool for axillary pathological complete response in node-positive breast cancer. International Journal of Medical Science. 2020; 7(11): 1–4.